Please login to the form below
Pierre Fabre
This page shows the latest Pierre Fabre news and features for those working in and with pharma, biotech and healthcare.
EC approves Atara and Pierre Fabre’s Ebvallo as monotherapy for Epstein-Barr patients
following the transfer of the Ebvallo Marketing Authorisation Application from Atara to Pierre Fabre. ... We are proud and excited to bring this innovative therapy to the marketplace, which will reinforce Pierre Fabre’s portfolio in oncology,
Latest news
-
EORTC and Pierre Fabre launch phase 3 trial for melanoma
The European Organisation for Research and Treatment of Cancer (EORTC) and health and beauty care company, Pierre Fabre, have begun a phase 3 study to assess a combination therapy for patients ... Pierre Fabre’s partnership with EORTC is now
-
Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
Drug approved in combination with Merck's KGaA's Erbitux. French pharma group Pierre Fabre’s Braftovi has been recommended for NHS use by the UK’s National Institute for Health ... Pierre Fabre is also looking to prove the Braftovi/Mektovi
-
UK pharma Code of Practice to change with digital times
Earlier this year, Martindale Pharma, Pierre Fabre, Janssen and Pharmasure were all named in adverts following serious breaches the Code.
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals
It also backed three targeted cancer drugs: Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) as a combination for BRAF V600-positive melanoma; and Eli Lilly’s
-
A unique ecosystem
Medicen has seen very positive results in 2016, with 20% business growth and the arrival of 80 new members, including mid-size pharma company Pierre Fabre.
More from news
Approximately 3 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
The state of pharma customer experience
On a company level, the three firms leading in the provision of customer experience through non-digital channels were Novo Nordisk (with a CXQ score of 69), Gilead (68) and Pierre ... Fabre (also 68).
-
Deal Watch November 2015
Acquisition - assets. Marketed global dermatology portfolio. 724. Array BioPharma. Pierre Fabre.
-
Investing in the future of R&D
The bank, set up by the EU in 1958, has funded pharmaceutical activities before - Pierre Fabre and Ferrer Pharmaceutical are among the firms whose projects have been financed under its
-
Unravelling the complex patient journey: can it be done?
Antoine has over ten years of new product launch and brand development experience in the pharmaceutical industry with roles at GSK, Novartis, Pierre Fabre Oncologie and Roche.
-
Country report: The healthcare market in France
Evolution of the pharmaceutical market. Market dominance. The majority of drug research, development and production in France is carried out by the top five French players: Sanofi, Servier, Ipsen, Pierre Fabre
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Cellectis’ Mathieu Simon will serve as interim chief medical officer
His other roles include senior vice president, global pharma operations for Pierre Fabre and has held numerous senior roles with Wyeth Pharmaceuticals, before it was acquired by Pfizer for $68bn back
-
Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon
Former GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage biopharmaceutical company Alzheon. ... Garnier then became chief executive officer of Pierre Fabre Laboratories and
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
EPG Health
Pierre Fabre, Roche, Sandoz, Sanofi, Seagen, Takeda, Teva, ViiV Healthcare.
-
PEGASUS WINS COMMUNIQUÉ 2015 ‘EXCELLENCE IN PATIENT/CONSUMER HEALTH PROGRAMMES’ AWARD FOR RARE DISEASE AWARENESS CAMPAIGN
Pegasus’s clients currently include GSK, Pfizer, Boehringer Ingelheim, Bayer, Thornton &Ross, Holland &Barrett, Sanofi, Bio-Oil, Danone, Homedics, Novo Nordisk and Pierre Fabre.
-
PEGASUS STRENGTHENS ITS PHARMA TEAM WITH TWO STAFF APPOINTMENTS
Pegasus’s clients currently include GSK, Pfizer, Boehringer Ingelheim, Bayer, Thornton &Ross, Holland &Barrett, Sanofi, Bio-Oil, Danone, Homedics, Novo Nordisk and Pierre Fabre.
-
Pegasus picks up “Specialist Consultancy of the Year” at the PRCA Awards 2014
Pegasus’s clients currently include GSK, Pfizer, Boehringer Ingelheim, Bayer, Thornton &Ross, Holland &Barrett, Sanofi, Bio-Oil, Danone, Homedics, Novo Nordisk and Pierre Fabre.
-
Pegasus supports unique theatrical performance as part of the 9th UK Dementia Congress
Pegasus’s clients currently include GSK, Pfizer, Boehringer Ingelheim, Bayer, Thornton &Ross, Holland &Barrett, Sanofi, Bio-Oil, Danone, Homedics, Novo Nordisk and Pierre Fabre.
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
